ANI Pharmaceuticals announces royalty obligation buyout for Iluvien, Yutiq
ANI Pharmaceuticals (ANIP) has completed the buyout of its 3.125% perpetual royalty obligation to SWK Funding on worldwide net revenues of ...
ANI Pharma wins Overweight rating at J.P. Morgan on growth prospects
J.P. Morgan on Wednesday launched its coverage of ANI Pharmaceuticals (NASDAQ:ANIP) with an Overweight recommendation and a year-end price target of $85 per share, citing the specialty pharma ...